Expanded strategic deal includes equipment and co-commercialization.
LAVAL, Que. — ProMetic Life Sciences Inc. has expanded its strategic collaboration with Sartorius Stedim Biotech (SSB) to include a contribution of equipment to ProMetic’s plasma purification facility, plus an agreement for the co-commercialization of its Plasma Protein Purification System (PPPS) globally.
SSB, a French supplier of equipment to the biopharmaceutical market, will provide filtration equipment and other consumables that will be integrated in ProMetic’s plasma purification plant, which is to be operational in the fourth quarter.
Financial details of SSB’s contribution were not released, but ProMetic, a biopharmaceutical company based in Laval, Que., said it represents a significant investment over the next three years as plasma derived products manufactured in the GMP facility undergo regulatory approval.
The agreement also confirms SSB as a preferred supplier of filtration equipment and consumables for ProMetic’s PPPS licensees.
ProMetic’s PPPS system employs powerful affinity separation materials in a multi-step process to extract and purify proteins at high yields.
ProMetic and SSB will also expand their co-commercialization efforts of the PPPS technology to include respective technological and engineering solution transfers. Expanded global co-commercialization efforts are expected to accelerate penetration of Asia and other emerging markets.
ProMetic’s said its plasma purification facility in Laval, created for the development and manufacturing of high-value plasma-derived therapeutics, will become a technological showroom for the PPPS technology.